Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 286 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Continuation therapy Clear all
Recruiting Not applicable Interventional

A Study of a Side Effects and Resource Navigation Program for People With Cancer

NCT07646847
View directory record Official record
Conditions
Kidney Cancer, Bladder Cancer, Breast Cancer, Lung Cancer
Interventions
Immunotherapy CARE Program
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Continuation Therapy in Advanced NSCLC

NCT03083808
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
Greg Durm, MD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Results available

Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status

NCT00813943
View directory record Official record
Conditions
Glioblastoma
Interventions
Cilengitide (2-times weekly), cilengitide (5-times weekly), Temozolomide, Radiotherapy
Drug · Radiation
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Fontan-associated Hepatic Stiffness and the Efficacy of Udenafil in Reducing Liver Stiffness

NCT03430583
View directory record Official record
Conditions
Single Ventricle Heart Disease
Interventions
Udenafil
Drug
Lead sponsor
Mezzion Pharma Co. Ltd
Industry
Eligibility
12 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Aurora, Colorado • Wilmington, Delaware • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 11, 2026, 4:50 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

NCT03719131
View directory record Official record
Conditions
Cutaneous Melanoma, Stage III, Cutaneous Melanoma, Stage IV, Stage III Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma, Unresectable Melanoma
Interventions
Nivolumab, Rituximab and Hyaluronidase Human, Ipilimumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Not applicable Interventional

Social Cognition and Interaction Training for Autism

NCT02382172
View directory record Official record
Conditions
Autism, Social Behavior
Interventions
Social Cognition and Interaction Training for Autism (SCIT-A), Treatment as Usual (TAU)
Behavioral · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
10 Years to 69 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Carrboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 11, 2026, 4:50 PM EDT
Enrolling by invitation Phase 4 Interventional

Trial of Reducing Inpatient Antibiotic Durations in Children

NCT07322146
View directory record Official record
Conditions
Pneumonia, Skin and Soft Tissue (SST) Infection, Urinary Tract Infections (UTIs)
Interventions
Study Drug Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Days to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Results available

Interleukin-1 Trap to Treat Autoinflammatory Diseases

NCT00094900
View directory record Official record
Conditions
Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset
Interventions
IL-1 Trap
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2014 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Results available

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients

NCT01784068
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Nilotinib followed by treatment-free
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
10
States / cities
Fort Myers, Florida • Miami Lakes, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 11, 2026, 4:50 PM EDT
Active, not recruiting Not applicable Interventional

Amplatzer Amulet LAAO vs. NOAC

NCT04226547
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Left Atrial Appendage Occlusion (Amplatzer Amulet LAA Occluder), Non-Vitamin K Oral Antagonists
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
79
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

NCT02301143
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Gemcitabine, Chemoradiation, Capecitabine, Surgery
Drug · Procedure
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 11, 2026, 4:50 PM EDT
Not listed Phase 4 Interventional

Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel

NCT03082573
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
H.P. Acthar gel
Drug
Lead sponsor
Iraj Sabahi Research Inc.
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Pleasanton, California • Turlock, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 11, 2026, 4:50 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

NCT02443077
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Interventions
Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Laboratory Biomarker Analysis, Melphalan, Pharmacogenomic Study, Placebo Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
280
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Tucson, Arizona + 202 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Not applicable Interventional

Self-guided Depression Treatment on Long-duration Spaceflights: A Continuation Study

NCT00906581
View directory record Official record
Conditions
Depression
Interventions
Computer-based Problem-Solving Treatment
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
30 Years to 60 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 11, 2026, 4:50 PM EDT
Withdrawn Phase 2 Interventional

Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC

NCT05608369
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Hypopharynx
Interventions
Cisplatin, Radiation therapy, Vorinostat
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 11, 2026, 4:50 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Comparison Study of Insulin Glargine and NPH Insulin

NCT01854723
View directory record Official record
Conditions
Diabetes
Interventions
Switching to NPH insulin, Continuation of insulin glargine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
Up to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Phase 4 Interventional

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

NCT05657860
View directory record Official record
Conditions
Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Interventions
Guanfacine Extended Release, Placebo
Drug · Other
Lead sponsor
Maimonides Medical Center
Other
Eligibility
6 Years to 35 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Not applicable Interventional

Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder

NCT01981317
View directory record Official record
Conditions
Obsessive Compulsive Disorder, Stepped Care Cognitive Behavioral Therapy
Interventions
Stepped Care Cognitive Behavioral Therapy, Cognitive Behavioral Therapy
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 11, 2026, 4:50 PM EDT
Not listed Not applicable Interventional

Diet in the Management of Acromegaly

NCT05401084
View directory record Official record
Conditions
Acromegaly
Interventions
Diet
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 11, 2026, 4:50 PM EDT
Recruiting Not applicable Interventional

Contingency Management to Improve Medication for Opioid Use Disorder Continuation After the Emergency Department

NCT07129902
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Contingency Management, Usual care as prescribed by the ED physicians
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Not applicable Interventional Results available

A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

NCT05785832
View directory record Official record
Conditions
Type 2 Diabetes Treated With Insulin
Interventions
t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM, Standard Therapy plus continuous glucose monitoring (CGM)
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
Newport Beach, California • Atlanta, Georgia • Idaho Falls, Idaho + 16 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 11, 2026, 4:50 PM EDT
Recruiting Not applicable Interventional

Mechanisms Underlying the Efficacy of Prolonged Exposure

NCT05663151
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Prolonged Exposure Therapy for Posttraumatic Stress Disorder
Behavioral
Lead sponsor
VA Boston Healthcare System
Federal
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2025 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Phase 4 Interventional Results available

A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients

NCT00406848
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
duloxetine hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
65 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
23
States / cities
Pasadena, California • Sherman Oaks, California • Hamden, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2010 · Synced Sep 11, 2026, 4:50 PM EDT
Completed Phase 1 Interventional

Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

NCT01460498
View directory record Official record
Conditions
Leukemia
Interventions
Azacitidine (AZA), Tyrosine kinase inhibitor (TKI), Azacitidine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Sep 11, 2026, 4:50 PM EDT